IN 1995, the Cardiorenal Advisory Committee of the Food and Drug Administration, after a lengthy deliberation, unanimously decided that sublingual nifedipine should not officially be approved for the treatment of hypertensive emergencies. Despite this decision and despite authoritative voices1-4 warning against this practice, the use of short-acting nifedipine for what was perceived as hypertensive emergencies remained widespread in the United States and all over the globe.
Messerli FH, Grossman E. The Use of Sublingual Nifedipine: A Continuing Concern. Arch Intern Med. 1999;159(19):2259–2260. doi:https://doi.org/10.1001/archinte.159.19.2259
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: